Not CRISPR data: the image illustrates antibody quality for visualizing CRISPR experiment results.
Not CRISPR data: the image illustrates antibody quality for visualizing CRISPR experiment results.
TADA2B CRISPR/Cas9 KO Plasmid (h): sc-406224
- Target species: human
- 20 µg of transfection-ready, purified plasmid DNA; Suitable for up to 20 transfections
- TADA2B CRISPR/Cas9 Knockout (KO) Plasmid (h) is a pool of plasmids, each encoding Cas9 nuclease and a target-specific 20 nt guide RNA (gRNA) designed for maximum knockout efficiency using sequences derived from the GeCKO v2 library
- gRNA sequences direct Cas9 to induce site-specific double-strand breaks (DSBs) in the TADA2B genomic locus, resulting in gene knockout through non-homologous end joining (NHEJ)
- The puromycin resistance and RFP genes are flanked by LoxP sites, enabling removal of selection markers via Cre recombinase (Cre Vector: sc-418923) after establishing stable knockout cell lines
- Following transfection, gene knockout efficiency can be assayed by WB, IF or IHC using antibody: TADA2B Antibody (MB-56): sc-130479
Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
TADA2B CRISPR/Cas9 KO Plasmid (h) | sc-406224 | 20 µg | $397.00 |
Overview
TADA2B (transcriptional adaptor 2B) is a core component of the ATAC histone acetyltransferase complex that supports transcription initiation by promoting acetylation of histone H3 and maintaining accessible chromatin. Through interactions with GCN5/KAT2A and related coactivator modules, TADA2B couples chromatin remodeling to RNA polymerase II–dependent gene expression programs. Its activity links to regulation of cell-cycle progression, differentiation-associated transcriptional networks, and genome-wide enhancer function. Altered regulation of ATAC/GCN5 axis components, including TADA2B, has been associated with dysregulated transcription and epigenetic states observed across cancer and neurodevelopment-relevant studies.
TADA2B CRISPR/Cas9 KO Plasmid (h) is a pool of plasmids designed for targeted disruption of the TADA2B gene in human cell lines. Each plasmid co-expresses a unique single guide RNA (sgRNA) targeting a distinct site within the TADA2B together with the Streptococcus pyogenes Cas9 nuclease. The plasmids also encode GFP, allowing fluorescent identification and enrichment of successfully transfected cells by fluorescence microscopy or flow cytometry.
The multi-guide design increases the likelihood of generating insertions or deletions (indels) that disrupt the TADA2B open reading frame following Cas9-mediated double-strand break formation. DNA breaks introduced by the CRISPR/Cas9 system are repaired through endogenous non-homologous end joining (NHEJ) pathways, frequently resulting in frameshift mutations that abolish TADA2B protein expression.
This CRISPR knockout system enables efficient generation of TADA2B-deficient cell models for investigation of TADA2B signaling, functional genomics studies, cancer biology research, and evaluation of therapeutic responses in human cell lines.
Key Features
- sgRNAs targeting TADA2B exon(s) critical for TADA2B function
- Co-expression of SpCas9 and sgRNA from a single plasmid for simplified delivery
- GFP reporter for identification of transfected cells
- Pool of plasmids targeting multiple TADA2B genomic sites to improve knockout efficiency
- Compatible with delivery by transfection
Design Variants
CRISPRs +/- HDRs
- gRNAs encoded by TADA2B CRISPR/Cas9 KO Plasmid (h) and TADA2B CRISPR/Cas9 KO Plasmid (h2) target distinct sites within the TADA2B locus. One or both targeting designs may be available. See Related Products for availability.
- HDR donor constructs encoded by TADA2B HDR Plasmid (h) and TADA2B HDR Plasmid (h2) contain a puromycin resistance cassette and an RFP reporter flanked by TADA2B homology arms to support homology-directed repair at defined TADA2B target sites corresponding to the CRISPR/Cas9 KO designs. HDR donor availability may vary. See Related Products for availability.
For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.